These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 2898045)

  • 21. Low doses of dasiglucagon consistently increase plasma glucose levels from hypoglycaemia and euglycaemia in people with type 1 diabetes mellitus.
    Hövelmann U; Olsen MB; Mouritzen U; Lamers D; Kronshage B; Heise T
    Diabetes Obes Metab; 2019 Mar; 21(3):601-610. PubMed ID: 30350477
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between Optimum Mini-doses of Glucagon and Insulin Levels when Treating Mild Hypoglycaemia in Patients with Type 1 Diabetes - A Simulation Study.
    Ranjan A; Wendt SL; Schmidt S; Madsbad S; Holst JJ; Madsen H; Knudsen CB; Jørgensen JB; Nørgaard K
    Basic Clin Pharmacol Toxicol; 2018 Mar; 122(3):322-330. PubMed ID: 28922582
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term administration of theophylline and glucose recovery after hypoglycaemia in patients with type 1 diabetes mellitus.
    Hvidberg A; Rosenfalck A; Christensen NJ; Hilsted J
    Diabet Med; 1998 Jul; 15(7):608-14. PubMed ID: 9686702
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of subcutaneous, low-dose glucagon on insulin-induced mild hypoglycaemia in patients with insulin pump treated type 1 diabetes.
    Ranjan A; Schmidt S; Madsbad S; Holst JJ; Nørgaard K
    Diabetes Obes Metab; 2016 Apr; 18(4):410-8. PubMed ID: 26743775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glucagon and diabetes. II. Complete suppression of glucagon by insulin in human diabetes.
    Warne GL; Alford FP; Chisholm DJ; Court J
    Clin Endocrinol (Oxf); 1977 Apr; 6(4):277-84. PubMed ID: 862206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hypoglycaemia in childhood diabetes. II. Effect of subcutaneous or intramuscular injection of different doses of glucagon.
    Aman J; Wranne L
    Acta Paediatr Scand; 1988 Jul; 77(4):548-53. PubMed ID: 3394508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes.
    Christensen M; Calanna S; Sparre-Ulrich AH; Kristensen PL; Rosenkilde MM; Faber J; Purrello F; van Hall G; Holst JJ; Vilsbøll T; Knop FK
    Diabetes; 2015 Jan; 64(1):72-8. PubMed ID: 25053587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cross-Validation of a Glucose-Insulin-Glucagon Pharmacodynamics Model for Simulation Using Data From Patients With Type 1 Diabetes.
    Wendt SL; Ranjan A; Møller JK; Schmidt S; Knudsen CB; Holst JJ; Madsbad S; Madsen H; Nørgaard K; Jørgensen JB
    J Diabetes Sci Technol; 2017 Nov; 11(6):1101-1111. PubMed ID: 28654314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alanine and terbutaline in treatment of hypoglycemia in IDDM.
    Wiethop BV; Cryer PE
    Diabetes Care; 1993 Aug; 16(8):1131-6. PubMed ID: 8375243
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nonaqueous, Mini-Dose Glucagon for Treatment of Mild Hypoglycemia in Adults With Type 1 Diabetes: A Dose-Seeking Study.
    Haymond MW; Redondo MJ; McKay S; Cummins MJ; Newswanger B; Kinzell J; Prestrelski S
    Diabetes Care; 2016 Mar; 39(3):465-8. PubMed ID: 26861921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog.
    Hövelmann U; Bysted BV; Mouritzen U; Macchi F; Lamers D; Kronshage B; Møller DV; Heise T
    Diabetes Care; 2018 Mar; 41(3):531-537. PubMed ID: 29273578
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Abnormal glucose counterregulation in insulin-dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion.
    Bolli G; de Feo P; Compagnucci P; Cartechini MG; Angeletti G; Santeusanio F; Brunetti P; Gerich JE
    Diabetes; 1983 Feb; 32(2):134-41. PubMed ID: 6337896
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prospective study evaluating the use of nasal glucagon for the treatment of moderate to severe hypoglycaemia in adults with type 1 diabetes in a real-world setting.
    Seaquist ER; Dulude H; Zhang XM; Rabasa-Lhoret R; Tsoukas GM; Conway JR; Weisnagel SJ; Gerety G; Woo VC; Zhang S; Carballo D; Pradhan S; Piché CA; Guzman CB
    Diabetes Obes Metab; 2018 May; 20(5):1316-1320. PubMed ID: 29504662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prehospital treatment of severe hypoglycaemia: a comparison of intramuscular glucagon and intravenous glucose.
    Carstens S; Sprehn M
    Prehosp Disaster Med; 1998; 13(2-4):44-50. PubMed ID: 10346406
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
    Villaume C; Beck B; Kolopp M; Toussain P; Debry G
    Biomed Pharmacother; 1986; 40(2):61-4. PubMed ID: 2875745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New Fast Acting Glucagon for Recovery from Hypoglycemia, a Life-Threatening Situation: Nasal Powder and Injected Stable Solutions.
    La Sala L; Pontiroli AE
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638984
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Epipen as an alternative to glucagon in the treatment of hypoglycemia in children with diabetes.
    Monsod TP; Tamborlane WV; Coraluzzi L; Bronson M; Yong-Zhan T; Ahern JA
    Diabetes Care; 2001 Apr; 24(4):701-4. PubMed ID: 11315834
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of glucagon response in glucose counter-regulation in type 1 (insulin-dependent) diabetics: absence of recovery after prolonged optimal insulin therapy.
    Bolli G; Calabrese G; De Feo P; Compagnucci P; Zega G; Angeletti G; Cartechini MG; Santeusanio F; Brunetti P
    Diabetologia; 1982 Feb; 22(2):100-5. PubMed ID: 7037510
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An insulin-dependent hypoglycaemia induced by electroacupuncture at the Zhongwan (CV12) acupoint in diabetic rats.
    Chang SL; Lin JG; Chi TC; Liu IM; Cheng JT
    Diabetologia; 1999 Feb; 42(2):250-5. PubMed ID: 10064107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duration of type I diabetes affects glucagon and glucose responses to insulin-induced hypoglycemia.
    Lorenzi M; Bohannon N; Tsalikian E; Karam JH
    West J Med; 1984 Oct; 141(4):467-71. PubMed ID: 6390972
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.